Published in Hepatology on October 01, 2010
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res (2015) 0.99
Present and future therapies of hepatitis B: From discovery to cure. Hepatology (2015) 0.96
Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections. Antivir Ther (2014) 0.80
Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents. Emerg Microbes Infect (2013) 0.79
Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection. PLoS One (2016) 0.78
A ubiquitin independent degradation pathway utilized by a hepatitis B virus envelope protein to limit antigen presentation. PLoS One (2011) 0.77
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell (1996) 8.25
Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A (1987) 8.11
Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 3.84
Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem Sci (1994) 3.32
Protein glucosylation and its role in protein folding. Annu Rev Biochem (2000) 3.09
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol (2007) 1.77
A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology (1999) 1.75
Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol (1975) 1.75
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med (1998) 1.64
Purification and enzymatic properties of peptide:N-glycanase from C3H mouse-derived L-929 fibroblast cells. Possible widespread occurrence of post-translational remodification of proteins by N-deglycosylation. J Biol Chem (1994) 1.47
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A (1997) 1.46
Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis (2007) 1.37
New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection. Viral Immunol (1993) 1.30
Envelopment of the hepatitis B virus nucleocapsid. Virus Res (2004) 1.30
Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology (2000) 1.27
Demonstration that Golgi endo-alpha-D-mannosidase provides a glucosidase-independent pathway for the formation of complex N-linked oligosaccharides of glycoproteins. J Biol Chem (1990) 1.26
An analytical and structural database provides a strategy for sequencing O-glycans from microgram quantities of glycoproteins. Anal Biochem (2002) 1.25
Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu Rev Cell Dev Biol (1999) 1.19
Inhibition of glucose trimming by castanospermine results in rapid degradation of unassembled major histocompatibility complex class I molecules. J Biol Chem (1993) 1.18
Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J Virol (1998) 1.17
Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol (2006) 1.03
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99
Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology (2002) 0.97
Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. J Immunol (1999) 0.97
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother (2009) 0.95
Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J Virol (2005) 0.90
Hypothesis: a glycoprotein-degradation complex formed by protein-protein interaction involves cytoplasmic peptide:N-glycanase. Biochem Biophys Res Commun (2003) 0.89
The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate. Virology (2007) 0.86
Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother (1994) 0.86
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol (2002) 0.83
Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity? DNA Cell Biol (2006) 0.81
Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. Virology (2008) 0.81
Cytotoxic T lymphocyte activity to hepatitis B virus DNA-transfected HepG2 cells in patients with chronic hepatitis B. Gastroenterol Jpn (1993) 0.80
Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture. J Biol Chem (1988) 0.79
Pleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes. J Biol Chem (2001) 0.78
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol (2010) 2.98
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol (2007) 2.40
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol (2008) 2.03
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol (2008) 1.96
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells. J Virol (2002) 1.93
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem (2004) 1.78
The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol (2007) 1.77
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitis. Proc Natl Acad Sci U S A (2013) 1.42
A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent. Nat Immunol (2005) 1.41
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother (2012) 1.31
Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res (2013) 1.29
Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol (2008) 1.28
Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology (2004) 1.27
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog (2013) 1.22
Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS (2013) 1.21
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res (2009) 1.13
Antiviral effect of interferon lambda against West Nile virus. Antiviral Res (2009) 1.12
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology (2012) 1.10
The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res (2012) 1.10
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res (2010) 1.09
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol (2010) 1.08
GB virus B infection of the common marmoset (Callithrix jacchus) and associated liver pathology. J Gen Virol (2004) 1.07
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
Calculating the return on investment of mobile healthcare. BMC Med (2009) 1.05
Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci (2008) 1.05
Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A (2014) 1.04
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother (2009) 1.04
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog (2013) 1.04
A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics (2003) 1.03
Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol (2002) 1.03
Integration of woodchuck hepatitis and N-myc rearrangement determine size and histologic grade of hepatic tumors. Hepatology (2004) 1.02
Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues. Anal Chem (2013) 1.01
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2008) 0.99
Competitive inhibitor of cellular α-glucosidases protects mice from lethal dengue virus infection. Antiviral Res (2011) 0.99
Epitopes derived by incidental translational frameshifting give rise to a protective CTL response. J Immunol (2006) 0.99
Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted virions. Virology (2002) 0.98
Fucosylated glycoproteins as markers of liver disease. Dis Markers (2008) 0.98
Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology (2002) 0.97
Transrenal DNA as a diagnostic tool: important technical notes. Ann N Y Acad Sci (2004) 0.97
Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model. Antiviral Res (2004) 0.96
Hepatitis B virus-mediated changes of apolipoprotein mRNA abundance in cultured hepatoma cells. J Virol (2003) 0.96
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother (2009) 0.95
Glyco- and peptidomimetics from three-component Joullié-Ugi coupling show selective antiviral activity. J Am Chem Soc (2005) 0.95
Enforced expression of Spi-B reverses T lineage commitment and blocks beta-selection. J Immunol (2005) 0.95
Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology (2012) 0.95
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res (2011) 0.93
A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol (2013) 0.93
Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology (2013) 0.93
Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther (2004) 0.93
MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One (2012) 0.93
Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One (2012) 0.92
Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol (2009) 0.92
Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother (2010) 0.92
Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol (2008) 0.92
Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res (2013) 0.91
Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope. J Immunol (2006) 0.90